- The event is co-organized by Winhealth Pharma

The Hainan Boao Lecheng International Medical Tourism Pilot Zone ("Lecheng 
Pilot Zone")'s virtual promotional event to explain the favorable investment 
policies put in place for Japanese businesses, hosted by the administration of 
the Hainan Boao Lecheng International Medical Tourism Pilot Zone ("Lecheng 
Administration") and co-organized by Hong Kong Winhealth Pharma Group 
("Winhealth Pharma"), Boao Winhealth Rare Disease Medical Center ("Rare Disease 
Center") and EPS International Holding Co., Ltd. (EPSI), was held in Boao, 
China on September 16, 2021.

Lecheng Administration director Gu Gang said, "As a medical park open to 
working with companies and organizations outside of China, Lecheng values the 
investments from Japanese pharmaceutical manufacturers. Lecheng is committed to 
helping these firms using the pilot zone as a jumping off point from which to 
promote and commercialize their innovative products in China, giving patients 
across the country an opportunity to benefit from new and efficient medical 
technologies from Japan."

According to Hainan Provincial Food and Drug Administration deputy director Li 
Yunda, 5,380 patients have to date received treatment that was provided by 173 
categories of drugs and medical devices imported in response to the urgent 
clinical needs since the State Council granted the People's Government of 
Hainan Province rights to approve the import of this range of products in 2018.

Lecheng Administration deputy director Lv Xiaolei explained that according to 
the Opinions on Supporting the Hainan Free Trade Port in Implementing Certain 
Special Measures for Improving Market Access, Lecheng Pilot Zone was provided 
with an opportunity to test new favorable policies used to streamline the 
approval process. With the support of the Hainan Provincial Health Commission, 
Hainan Provincial Food and Drug Administration and Haikou Customs, the approval 
time for imported medical devices will be reduced from 27 days on average to 
3-7 days.

Hainan Real World Data Research Institute executive director Chen Pingyan 
pointed out that high-quality data, good design, and accurate analysis and 
result interpretation play a key role in the process of converting real-world 
data to evidence. Chen Pingyan also shared an example of the successful rollout 
of licensed medical devices in China through Lecheng's Real World Study (RWS) 
program. He said the RWS program will facilitate the launch of drugs by making 
full use of the opportunity to test revolutionary measures meant to help 
international pharmaceutical firms register and market their products in China. 

Hong Kong Winhealth Pharma Group vice president Xiao Li said, "With the support 
of Lecheng Pilot Zone, the Rare Disease Center has rolled out 31 medical 
devices for the treatment of rare diseases since its establishment. The center 
is committed to providing Chinese patients with the world's most advanced 
solutions for rare disease treatment by collaborating with partners worldwide. 
In addition, the center plans to leverage the pilot zone's RWS program to 
accelerate the approval for rare disease-related devices that have been 
accepted into other markets in a move to benefit Chinese patients afflicted 
with such diseases.

With the increasing openness of the Lecheng Pilot Zone, the group plans to 
continue promoting and deepening the long-term partnerships between Lecheng and 
Japanese businesses by capitalizing on the Rare Disease Center's decision to 
bring in Japanese medical devices in a move to provide Chinese patients with an 
access to innovative medical solutions from Japan.

SOURCE:  HK Winhealth Pharma Group